Showing 2701-2710 of 3315 results for "".
- Edward J. Holland, MD, to Join Alcon as Member of the Research and Development Teamhttps://modernod.com/news/edward-j-holland-md-to-join-alcon-as-member-of-the-research-and-development-team/2481000/Alcon announced that Edward J. Holland, MD, will join Alcon as a member of the Research and Development (R&D) team. Dr. Holland is a thought leader in ophthalmology, specializing in the field of cornea and the ocular surface. He will serve as an enterprise Senior Scientifi
- Adverum Biotechnologies Granted Priority Medicines (PRIME) Designation by European Medicines Agency for ADVM-022 in Wet AMDhttps://modernod.com/news/adverum-biotechnologies-granted-priority-medicines-prime-designation-by-european-medicines-agency-for-advm-022-in-wet-amd/2480943/Adverum Biotechnologies announced that the European Medicines Agency (EMA) has granted ADVM-022 Priority Medicines (PRIME) designation for the treatment of wet age-related macular degeneration (AMD). Adverum’s lead gene therapy candidate, ADVM-022, is a one-time, intr
- OliX Pharmaceuticals Subsidiary mCureX Announces mRNA Technology Collaboration with ToolGen for Rare Eye Diseasehttps://modernod.com/news/olix-pharmaceuticals-subsidiary-mcurex-announces-mrna-technology-collaboration-with-toolgen-for-rare-eye-disease/2480920/OliX Pharmaceuticals, a\ developer of RNAi therapeutics, announced that the company’s subsidiary, mCureX Therapeutics, has recently signed a contract for joint research with ToolGen to advance the development of gene therapy for rare eye diseases, leveraging mCureX’s mRNA technol
- Aurion Biotech Appoints Michael Goldstein, MD, as President and Chief Medical Officerhttps://modernod.com/news/aurion-biotech-appoints-dr-michael-goldstein-as-president-and-chief-medical-officer/2480904/Aurion Biotech announced it has appointed Michael Goldstein, MD, as president and chief medical officer. Dr. Goldstein will lead the company’s clinical strategy, development and operations; medical affairs; and manufacturing and quality teams for its first product candidate, a cel
- NIH: Gene Therapy for Rare Eye Disease Safe But Lacks Efficacy in Early Trialhttps://modernod.com/news/nih-gene-therapy-for-rare-eye-disease-safe-but-lacks-efficacy-in-early-trial/2480896/A 28-patient phase 1 gene therapy clinical trial for the degenerative retinal disease Leber hereditary optic neuropathy (LHON) found no significant safety concerns; however, treatment failed to improve or slow vision loss, with even the highest dose. LHON affects the optic nerve, which carries vi
- The Vision Council Announces that Version 3.13 of the Data Communication Standard is Now Availablehttps://modernod.com/news/the-vision-council-announces-that-version-313-of-the-data-communication-standard-is-now-available/2480893/The Vision Council announced the publication of Version 3.13 of the Standard for Data Communications. The standard, which is used by manufacturers of optical lab equipment and producers of software used in optical labs, was developed by The Vision Council’s Lens Proce
- "Artificial Intelligence in Ophthalmology 2022" Conference is Being Held Onlinehttps://modernod.com/news/artificial-intelligence-in-ophthalmology-2022-conference-is-being-held-online/2480884/The "Artificial Intelligence in Ophthalmology 2022" conference is being held online on June 3, 2022. The conference will feature an overview of artificial intelligence (AI), machine learning (ML) and deep learning (
- Alcon to Acquire Eysuvis and Inveltys from Kala Pharmaceuticalshttps://modernod.com/news/kala-pharmaceuticals-to-sell-eysuvis-and-inveltys-to-alcon/2480878/Alcon will significantly bolster its pharmaceutical offerings after reaching an agreement to acquire Kala Pharmaceuticals' commercial portfolio, which includes dry eye drug Eysuvis (loteprednol etabonate suspension 0.25%), and Inveltys (loteprednol etabonate
- Brim Biotechnology and Ora Announce Partnership to Accelerate Development of Regenerative Peptide Therapy, BRM421, for Dry Eyehttps://modernod.com/news/brim-biotechnology-and-ora-inc-announce-new-partnership-to-accelerate-development-of-regenerative-peptide-therapy-brm421-for-dry-eye-syndrome/2480867/Brim Biotechnology announces it has entered into a new strategic partnership with Ora Inc. for the late-stage clinical development of lead drug candidate, BRM421, for dry eye syndrome (DES). Brim intends to initiate phase 3 clinical studies with Ora’s support later this year.
- Nova Eye Medical Reports Canaloplasty Data Demonstrating Sustained Reduction in IOP with iTrackhttps://modernod.com/news/nova-eye-medical-reports-canaloplasty-data-demonstrating-sustained-reduction-in-iop-with-itrack/2480849/Nova Eye Medical reported the recent publication of three investigator-led, retrospective case series which evaluated the long-term effectiveness of canaloplasty in patients with open-angle glaucoma (OAG) over 36- and 48-month periods, and in post-keratoplasty patients. Performed b